MPM BioImpact LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001687078

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2026 · 37 positions · Total reported value $1.64B · Top-10 concentration 55.3% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.2% · 7 new · 21 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, MPM BioImpact LLC disclosed 37 equity positions with a combined reported value of $1.64B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were CGEM ($177.21M), AKTS ($155.86M), LQDA ($110.52M). By sector, the heaviest allocations are Health Care 98.7%, Other 1.3%. Versus the prior quarter, allocation shifted toward Health Care (+0.7pp) and away from Other (-0.7pp).

Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q2 2026 were RARE ($47.35M), BIOA ($40.87M), TSHA ($30.64M).

Of the 11 positions fully exited versus the prior quarter, the largest were AGIO ($44.19M), XENE ($34.23M), EVMN ($33.47M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • RARE ULTRAGENYX PHARMACEUTICAL IN · $47.35M
  • BIOA BIOAGE LABS INC · $40.87M
  • TSHA TAYSHA GENE THERAPIES INC · $30.64M
  • ZURA ZURA BIO LTD · $26.39M
  • ANL ADLAI NORTYE LTD · $22.27M
  • ANNX ANNEXON INC · $20.24M
  • TRDA ENTRADA THERAPEUTICS INC · $9.22M

Fully Exited (vs previous quarter)

  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $44.19M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $34.23M
  • EVMN EVOMMUNE INC · prev qtr: $33.47M
  • CYTK CYTOKINETICS INC · prev qtr: $32.95M
  • CRVS CORVUS PHARMACEUTICALS INC · prev qtr: $24.50M
  • CLYM CLIMB BIO INC · prev qtr: $17.77M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · prev qtr: $17.29M
  • ZYME ZYMEWORKS INC · prev qtr: $14.15M

Insider Transactions (Form 4)

Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-106989 (status: Approved), registered 2016-01-04
  • Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 14 private funds, of which 3 hedge funds

Portfolio Structure

  • 37 positions · $1.64B reported value (Q2 2026)
  • Top 10 holdings = 55.3% of reported value
  • Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
  • Average position size: $44.32M

Sector Tilt

  • Health Care 98.7%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 98.7%
Other 1.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 9.73M $177.21M 10.81%
10.81%
Add
2 4.84M $155.86M 9.50%
9.50%
Hold
3 1.39M $110.52M 6.74%
6.74%
Reduce
4 492.48K $92.23M 5.62%
5.62%
Reduce
5 771.03K $67.04M 4.09%
4.09%
Reduce
6 1.62M $65.85M 4.01%
4.01%
Reduce
7 1.12M $63.78M 3.89%
3.89%
Reduce
8 3.67M $60.13M 3.67%
3.67%
Reduce
9 3.07M $57.32M 3.50%
3.50%
Reduce
10 2.02M $56.82M 3.46%
3.46%
Reduce
11 1.23M $56.46M 3.44%
3.44%
Reduce
12 1.42M $47.35M 2.89%
2.89%
New
13 2.42M $45.20M 2.76%
2.76%
Add
14 336.35K $44.82M 2.73%
2.73%
Add
15 1.92M $42.69M 2.60%
2.60%
Add
16 420.00K $40.94M 2.50%
2.50%
Reduce
17 1.67M $40.87M 2.49%
2.49%
New
18 933.41K $34.35M 2.10%
2.10%
Reduce
19 1.61M $31.29M 1.91%
1.91%
Reduce
20 204.03K $31.18M 1.90%
1.90%
Reduce
21 4.50M $30.64M 1.87%
1.87%
New
22 1.33M $29.15M 1.78%
1.78%
Reduce
23 1.16M $28.10M 1.71%
1.71%
Reduce
24 4.47M $26.39M 1.61%
1.61%
New
25 92.64K $25.15M 1.53%
1.53%
Hold
26 723.31K $23.67M 1.44%
1.44%
Reduce
27 1.94M $22.27M 1.36%
1.36%
New
28 137.21K $21.13M 1.29%
1.29%
Add
29 987.45K $20.98M 1.28%
1.28%
Reduce
30 1.88M $20.38M 1.24%
1.24%
Add
31 322.01K $20.27M 1.24%
1.24%
Reduce
32 3.54M $20.24M 1.23%
1.23%
New
33 202.11K $14.19M 0.86%
0.86%
Reduce
34 1.25M $9.22M 0.56%
0.56%
New
35 1.04M $5.51M 0.34%
0.34%
Add
36 1.30M $719.54K 0.04%
0.04%
Reduce
37 80.14K $28.85K 0.00%
0.00%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Low-confidence forecast This fund replaces about 29% of its Top-10 each quarter and backtests at F1 70% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 70% · recall 70% · F1 70% · avg rank error 3.1 · Top-10 turnover 29%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 60% 60% 60% CGEM · IOVA · OLMA · GERN · ITOS · ALXO · MLTX · CRNX · KRTX · INSM CGEM · GERN · IOVA · ZNTL · ITOS · STRO · CRNX · OLMA · MDGL · NTRA
2024-Q2 70% 70% 70% CGEM · GERN · IOVA · ZNTL · ITOS · STRO · CRNX · OLMA · MDGL · NTRA CGEM · INSM · OLMA · ITOS · CRNX · MDGL · IOVA · NTRA · MIRM · RARE
2024-Q3 70% 70% 70% CGEM · INSM · OLMA · ITOS · CRNX · MDGL · NTRA · IOVA · RARE · MIRM CGEM · INSM · OLMA · RNAM · CRNX · EWTX · IOVA · NTRA · RCKT · MIRM
2024-Q4 70% 70% 70% CGEM · INSM · RNAM · OLMA · CRNX · EWTX · IOVA · NTRA · RCKT · MIRM CGEM · CRNX · EWTX · INSM · NTRA · MIRM · IRON · LNTH · ZLAB · RNAM
2025-Q1 70% 70% 70% CGEM · CRNX · EWTX · INSM · NTRA · MIRM · RNAM · IRON · PTCT · LNTH CGEM · MDGL · ZLAB · EWTX · LNTH · PTCT · NTRA · TRVI · CRNX · RNAM
2025-Q2 70% 70% 70% CGEM · MDGL · ZLAB · PTCT · EWTX · TRVI · LNTH · CRNX · NTRA · RNAM CGEM · MDGL · ZLAB · GH · SPRY · EWTX · RNAM · PTCT · TRVI · ORIC
2025-Q3 80% 80% 80% CGEM · MDGL · ZLAB · EWTX · GH · SPRY · RNAM · PTCT · TRVI · ORIC MDGL · CGEM · RNAM · TRVI · EWTX · PTCT · ZLAB · SNDX · ORIC · TARS
2025-Q4 60% 60% 60% MDGL · CGEM · RNAM · TRVI · EWTX · PTCT · ZLAB · XENE · ORIC · SNDX CGEM · MDGL · LQDA · TRVI · EWTX · RVMD · AGIO · QURE · PTCT · SNDX
2026-Q1 60% 60% 60% CGEM · MDGL · LQDA · RVMD · TRVI · EWTX · AGIO · QURE · PTCT · SNDX DBVT · CGEM · AKTS · LQDA · ALMS · EWTX · RVMD · AGIO · CORT · TRVI
2026-Q2 ★ 90% 90% 90% DBVT · CGEM · AKTS · LQDA · RVMD · ALMS · EWTX · AGIO · CORT · TRVI CGEM · AKTS · LQDA · RVMD · CORT · EWTX · TVTX · DBVT · TRVI · ALMS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did MPM BioImpact LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, MPM BioImpact LLC reported 37 equity positions worth $1.64B in aggregate; its largest disclosed positions were CGEM ($177.21M), AKTS ($155.86M), LQDA ($110.52M).

How large is MPM BioImpact LLC's portfolio?

MPM BioImpact LLC reported $1.64B of long equity holdings across 37 positions as of 2026-Q2. Top-10 holdings account for 55.3% of reported value.

What is MPM BioImpact LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/mpm-bioimpact/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →